Figure 3From: Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease modelMTT test of rimonabant. CB1 receptor antagonist, rimonabant, was added to the cultured HepG2 fatty cells at the concentrations of 1 mmol/L, 5 mmol/L, 10 mmol/L, 20 mmol/L and 40 mmol/L for 4 hr, 8 hr, 12 hr, 24 hr and 48 hr, respectively.Back to article page